GBE50 Attenuates Inflammatory Response by Inhibiting the p38 MAPK and NF-κB Pathways in LPS-Stimulated Microglial Cells

Figure 5

The effect of GBE50 on NF-κB p65, IκBα, and P-p38/p38 of BV2 cells activated by LPS. (a) The effect of GBE50 on a representative blot of NF-κB p65 protein expression in BV2 cells activated by LPS. (b) The effect of GBE50 on NF-κB p65 between treated and untreated groups. (c) The effect of GBE50 on a representative blot of the ratio of IκBα in BV2 cells activated by LPS. (d) The effect of GBE50 on the ratio of IκBα between treated and untreated groups. (e) The effect of GBE50 on a representative blot of the ratio of P-p38/p38 in BV2 cells activated by LPS. (f) The effect of GBE50 on the ratio of P-p38/p38 between treated and untreated groups. *𝑃<0.05, **𝑃<0.01 versus control and ^#𝑃<0.05, ^##𝑃<0.01 versus LPS group.

(a)

(b)

(c)

(d)

(e)

(f)